Fujisawa Pharmaceutical Company, Ltd.

Teruo Kyoto Oku

Masashi Hashimoto

Hiroshi Kayakiri

Tsutomu Toyonaka Teraji

Takashi Kamiya

Osamu Nakaguti

Yoshito Abe

Yuki Sawada

Hirokazu Tanaka

Shigeki Satoh

Yoshio Kawai

Takayuki Inoue

Yoshihisa Saito

Hitoshi Yamazaki

Tsuyoshi Mizutani

Eishiro Todo

Hiroyuki Setoi

Chiyoshi Kasahara

Takayuki Namiki

Noritsugu Yamasaki

Takehiko Ohkawa

Takafumi Imoto

Hitoshi Sawada

Takahiro Hiramura

Hitoshi Nakamura

Kazuyoshi Kuratani

Hidekazu Takeno

Natsuko Kayakiri

Akio Kuroda

Kozo Sawada

Yoshiharu Nakai

Norihiko Shimazaki

Hitoshi Hamashima

Youichi Shiokawa

Masahiro Nishikawa

Katsuya Nakamura

Osamu Onomura

Hiroshi Marusawa

Takao Takaya

Hisashi Takasugi

Keiji Hemmi

Kentaro Sato

Yoshihiko Kitaura

Masahiro Neya

Tadaaki Komori

Yoshiyuki Murai

Yukihisa Baba

Tatsuya Zenkoh

Hideo Hirai

Takumi Yatabe

Yuki Saitoh

Kousei Yoshihara

Yoshikuni Ito

Tosiyuki Yamamoto

Kouzou Sawada

Masakazu Kobayashi

Masakuni Okuhara

Seiji Hashimoto

Masanori Okamoto

Yasuhisa Tsurumi

Kazuhiko Ohne

Naoki Ishibashi

Eisaku Tsujii

Yasuharu Urano

Kouichi Tamura

Yoshikuni Itoh

Toshiro Iwamoto

Yoshihiro Yokota

Akira Katayama

Takayuji Inoue

Noriko Yoshida

Akira Nagashima

Yoshimitsu Nakajima

Osamu Nakagati

Naomi Hosogai

Atsushi Nomoto

Keizo Sogabe

Ciyoshi Kasahara

Kazuhiko Osoda

Osamu Nakaguit

A sulfonamide compound of the formula (I):R&#x2014;SONHCO&#x2014;A&#x2014;X&#x2014;R&#x2003;&#x2003;(I)wherein Ris alky, alkenyl, alkynyl and the like; A is an optionally substitutedheteropolycyclic group except benzimidazolyl, indolyl, 4,7-dihydrobenzimidazolyland 2,3-dihydrobenzoxazinyl; X is alkylene, oxa, oxa(lower)alkylene and the like; and Ris optionally substituted aryl, substituted biphenylyl and the like, a salt thereof and a pharmaceutical composition comprising the same. The sulfonamide compound is effective for the diseases treatable based on their blood sugar level-depressing activity, cGMP-PDE (especially PDE-V)-inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity, smooth muscle cell suppressing activity, and antiallergic activity.

Sulfonamide compounds and pharmaceutical use thereof

Sulfonamide compounds and uses thereof as medicines

Benzamide derivatives as vasopressin antagonists

A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substituted lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substituted amino; R is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R5 is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP-or TNF&agr;-medicated diseases.

Piperazine compounds as inhibitors of MMP or TNF

Benzimidazole derivatives

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Benzimidazole compounds

Sulfonamide compounds and medicinal use thereof

Heterocyclic compounds as bradykinin antagonists

A compound of formula (I) wherein A is a sulfonyl or a carbonyl; R,is an optionally substituted aryl, an optionally substituted heterocyclic group, an optionally substituted lower alkyl or an optionally substituted lower alkenyl; R,is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R,is an optionally substituted lower alkyl, an optionally substituted lower alkoxy, an optionally substituted aryloxy, an optionally substitued lower alkenyl, an optionally substituted aryl, an optionally substituted heterocyclic group or an optionally substitued amino; R,is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; R,is a hydrogen, an optionally substituted lower alkyl, an optionally substituted aryl or an optionally substituted heterocyclic group; and R,is a hydroxy or a protected hydroxy, and a pharmaceutically acceptable salt thereof. The compound of the present invention is useful as a medicament for prophylactic and therapeutic treatment of MMP- or TNF&agr;-mediated diseases.

This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc. and represented by general formula (I):

Benzamide derivatives having a vasopressin antagonistic activity

This invention relates to a heterocyclic compound of the formula

Benzimidazole compounds as bradykinin antagonists

The invention relates to a pharmaceutical composition for ophthalmic administration comprising a compound of the formula:

Bradykinin antagonist quinolines

Growing community of inventors

Osaka, Japan

Teruo Kyoto Oku